AIDS THERAPIES

SIV模型(无论是在体外还是在体内)都非常适合测试 HIV药物治疗由于SIVmne和HIV在#年的相似性 结构、基因组组织和疾病产生。的目标是 这个项目是为了开发一种有效的抗病毒疗法来治疗 在猕猴身上预防或治疗艾滋病。最终，这些信息可能 应用于人类的艾滋病。1997年，我们继续进行临床试验。 使用非循环药物的暴露前和暴露后预防 核苷膦(R)-9-(2-膦甲氧乙基)腺嘌呤(PMPA)， 对抗长尾猕猴的急性SIV感染。防止PMPA 在28天的治疗中，SIV感染被确定为 静脉接种SIV病毒24小时后启动(100% 感染剂量)。所有未经治疗、接种的猕猴都被感染了 与SIV合作。资助NIH合同AI65311和NIH赠款RR00166。蔡英文， 首页--期刊主要分类--期刊细介绍--期刊题录与文摘--期刊详细文摘内容 比肖夫伯格，N，利夫森，J.D.和莫顿，W.R.。 预防持续性肺炎的PMPA接种后治疗 感染严重地取决于发病的时间和持续时间。 关于治疗的问题。J.维罗尔。72 4256-4273,1998。

The SIV model (both in vitro and in vivo) is excellent for testing HIV drug therapies owing to the similarities between SIVmne and HIV in structure, genomic organization, and disease production. The goal of this project is to develop an effective antiviral therapy to either prevent or treat AIDS in macaques. Ultimately, this information may be applied to AIDS in humans. In 1997 we continued a clinical trial using preexposure and postexposure prophylaxis of an acyclic nucleoside phosphonate, (R)-9-(2-phosphonylmethoxyethl)adenine (PMPA), against acute SIV infection in longtailed macaques. PMPA prevented the establishment of SIV infection when a 28-day treatment was initiated 24 h after intravenous virus inoculation with SIV (100% infectious dose). All untreated, inoculated macaques became infected with SIV. FUNDING NIH contract AI65311 and NIH grant RR00166. Tsai, C-C., Emau, P., Follis, K.E., Beck, T.W., Benveniste, R.E., Bischofberger, N., Lifson, J.D., and Morton, W.R. The effectiveness of post-inoculation PMPA treatment for prevention of persistent SIVmne infection depends critically on the timing of initiation and duration of treatment. J. Virol. 72 4256-4273, 1998.